Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1668298

	registered interest
	date	08/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure the continued NHS funding of modulator therapies that are used to treat (a) children, (b) new patients and (c) other patients with cystic fibrosis.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	710
	answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.</p><p>NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/11/2023 10:43:17 answering member 4423 label Biography information for Will Quince
	tabling member	1409 label Biography information for Mr Gregory Campbell

1668572

	registered interest
	date	08/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure adequate levels of supply of medication prescribed for (a) epilepsy, (b) hormone replacement therapy and (c) ADHD.
	tabling member constituency	Bedford
	tabling member printed	Mohammad Yasin
	uin	882
	answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The Department has well-established procedures to deal with medicine shortages and works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.</p><p>We are aware of a current supply issue with generic lamotrigine 5mg dispersible tablets for epilepsy. We have issued comprehensive management guidance to the National Health Service highlighting the availability of alternative products.</p><p>There have been issues with the supply of a limited number of hormone replacement therapy (HRT) products, primarily due to very sharp increases in demand, but the supply position for many of those products has improved considerably over the last year. Only one of the 23 Serious Shortage Protocols issued since April 2022 remains in place. We continue to engage with suppliers individually to address these issues and improve resilience in the short, medium and long term. We are also holding quarterly roundtables with manufacturers, wholesalers and community pharmacists to monitor progress and agree what more needs to be done to ensure supply is sufficient to meet demand. The eighth HRT supply roundtable is expected to be held in January 2024.</p><p>We are aware of disruptions to the global supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD). Some issues are now resolving. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. We are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/11/2023 10:45:48 answering member 4423 label Biography information for Will Quince
	tabling member	4598 label Biography information for Mohammad Yasin

1668185

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sotrovimab
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the supply of anti-viral drug Sotrovimab for immunocompromised patients.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	501
	answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.</p><p>The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.</p><p>Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 500 question first answered 13/11/2023 10:39:41 answering member 4423 label Biography information for Will Quince
	tabling member	4769 label Biography information for Daisy Cooper